THE FUTURE OF ANTI-AMYLOID TRIALS
P.S. Aisen, J. Cummings, R. Doody, L. Kramer, S. Salloway, D.J. Selkoe, J. Sims, R.A. Sperling, B. Vellas, and the EU/US CTAD 2019 Task Force
The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer’s disease (AD) has had a major impact on the AD clinical research enterprise. However, positive signals in recent studies have reinvigorated support for the amyloid hypothesis and amyloid-targeting strategies. In December 2019, the EU-US Clinical Trials on Alzheimer’s Disease (CTAD) Task Force met to share learnings from these studies in order to inform future trials and promote the development of effective AD treatments. Critical factors that have emerged in studies of anti-amyloid monoclonal antibody therapies include developing a better understanding of the specific amyloid species targeted by different antibodies, advancing our insight into the mechanism by which those antibodies may reduce pathology, implementing more comprehensive repertoires of biomarkers into trials, and identifying appropriate doses. Studies suggest that Amyloid-Related Imaging Abnormalities – effusion type (ARIA-E) are a manageable safety concern and that caution should be exercised before terminating studies based on interim analyses. The Task Force concluded that opportunities for developing effective treatments include developing new biomarkers, intervening in early stages of disease, and use of combination therapies.
P.S. Aisen ; J. Cummings ; R. Doody ; L. Kramer ; S. Salloway ; D.J. Selkoe ; J. Sims ; R.A. Sperling ; B. Vellas ; and the EU/US CTAD 2019 Task Force (2020): The Future of Anti-Amyloid Trials. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2020.24